Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
A hexanucleotide GGGGCC expansion in intron 1 of chromosome 9 open reading frame 72 (C9orf72) gene is the most frequent cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The corresponding repeat-containing sense and antisense transcripts cause a gain of toxicity through the accumulation of RNA foci in the nucleus and deposition of dipeptide-repeat (DPR) proteins in the cytoplasm of the affected cells. We have previously reported on the potential of engineered artificial anti-C9orf72-targeting miRNAs (miC) targeting C9orf72 to reduce the gain of toxicity caused by the repeat-containing transcripts. In the current study, we tested the silencing efficacy of adeno-associated virus (AAV)5-miC in human-derived induced pluripotent stem cell (iPSC) neurons and in an ALS mouse model. We demonstrated that AAV5-miC transduces different types of neuronal cells and can reduce the accumulation of repeat-containing C9orf72 transcripts. Additionally, we demonstrated silencing of C9orf72 in both the nucleus and cytoplasm, which has an added value for the treatment of ALS and/or FTD patients. A proof of concept in an ALS mouse model demonstrated the significant reduction in repeat-containing C9orf72 transcripts and RNA foci after treatment. Taken together, these findings support the feasibility of a gene therapy for ALS and FTD based on the reduction in toxicity caused by the repeat-containing C9orf72 transcripts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · cited 1×
“Furthermore, it has been estimated that hundreds of protein products could be produced by a single mRNA, suggesting that even low levels of intronic transcripts are sufficient to cause the accumulation of toxic DPR proteins in the cell.(9,55)”
BackgroundDeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936 · cited 1×
“ALS and FTD patients display hundreds to a few thousand copies of the G4C2 repeat in the C9orf72 gene.(5) The contribution of this mutation to the pathogenesis of both diseases has been debated for several years, with the loss of C9orf72 function (haploinsufficiency), a gain of toxicity, or a combination of both being…”
A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409
Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis
Ling, S.-C., Polymenidou, M., & Cleveland, D. W. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.033 · Cited by 1,811 · cited 2×
“The contribution of this mutation to the pathogenesis of both diseases has been debated for several years, with the loss of C9orf72 function (haploinsufficiency), a gain of toxicity, or a combination of both being implicated.(7,8) Reduced C9orf72 mRNA levels in patients due to hypermethylation of the G4C2 repeat suppo…”
BackgroundNon–cell autonomous toxicity in neurodegenerative disorders: ALS and beyond
Ilieva, H., Polymenidou, M., & Cleveland, D. W. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200908164 · Cited by 1,008
The C9orf72 repeat expansion disrupts nucleocytoplasmic transport.
Zhang, K., Donnelly, C. J., Haeusler, A. R., Grima, J. C., Machamer, J. B., Steinwald, P., Daley, E. L., Miller, S. J., Cunningham, K. M., Vidensky, S., et al. (2015) · Nature · doi:10.1038/nature14973 · Cited by 982 · cited 2×
“In addition, DPRs disrupt the nucleocytoplasmic transport system of cells.(17,18) Furthermore, autopsy studies revealed that 90% of C9orf72 ALS and 50% of FTD patients have cytoplasmic aggregation of the transactive response DNA-binding protein of 43 kDa (TDP-43; encoded by TAR DNA binding protein [TARDBP]).”
BackgroundC9orf72 nucleotide repeat structures initiate molecular cascades of disease
Haeusler, A. R., Donnelly, C. J., Periz, G., Simko, E. A. J., Shaw, P. G., Kim, M.-S., Maragakis, N. J., Troncoso, J. C., Pandey, A., Sattler, R., et al. (2014) · Nature · doi:10.1038/nature13124 · Cited by 978
RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention
Donnelly, C. J., Zhang, P.-W., Pham, J. T., Haeusler, A. R., Mistry, N. A., Vidensky, S., Daley, E. L., Poth, E. M., Hoover, B., Fines, D. M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.015 · Cited by 877
Astrocytes from familial and sporadic ALS patients are toxic to motor neurons
Haidet-Phillips, A. M., Hester, M. E., Miranda, C. J., Meyer, K., Braun, L., Frakes, A., Song, S., Likhite, S., Murtha, M. J., Foust, K. D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1957 · Cited by 782 · cited 1×
“For example, it has been shown that astrocytes carrying the C9orf72 hexanucleotide expansion are toxic to motor neurons.(32,34) Although the underlying mechanisms remain unclear, intercellular seeding and transmission of DPRs between the two cell types could be a contributing factor.”
BackgroundJovičić, A., Mertens, J., Boeynaems, S., Bogaert, E., Chai, N., Yamada, S. B., Paul, J. W., Sun, S., Herdy, J. R., Bieri, G., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4085 · Cited by 598 · cited 1×
“In addition, DPRs disrupt the nucleocytoplasmic transport system of cells.(17,18) Furthermore, autopsy studies revealed that 90% of C9orf72 ALS and 50% of FTD patients have cytoplasmic aggregation of the transactive response DNA-binding protein of 43 kDa (TDP-43; encoded by TAR DNA binding protein [TARDBP]).”
Research works printed but not linked: 44
- Ferrari, 2011, FTD and ALS: a tale of two diseases, Curr. Alzheimer Res., 8, 273, 10.2174/156720511795563700 · DOI · Paper page
- Liscic, 2008, ALS and FTLD: two faces of TDP-43 proteinopathy, Eur. J. Neurol., 15, 772, 10.1111/j.1468-1331.2008.02195.x · DOI · Paper page
- Heutink, 2014, C9orf72; abnormal RNA expression is the key, Exp. Neurol., 262, 102, 10.1016/j.expneurol.2014.05.020 · DOI
- Gendron, 2014, Mechanisms of toxicity in C9FTLD/ALS, Acta Neuropathol., 127, 359, 10.1007/s00401-013-1237-z · DOI · Paper page
- Liu, 2017, c9orf72 Disease-Related Foci Are Each Composed of One Mutant Expanded Repeat RNA, Cell Chem. Biol., 24, 141, 10.1016/j.chembiol.2016.12.018 · DOI
- Cooper-Knock, 2014, Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions, Brain, 137, 2040, 10.1093/brain/awu120 · DOI · Paper page
- Zu, 2013, RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia, Proc. Natl. Acad. Sci. USA, 110, E4968, 10.1073/pnas.1315438110 · DOI · Paper page
- Wojciechowska, 2011, Cellular toxicity of expanded RNA repeats: focus on RNA foci, Hum. Mol. Genet., 20, 3811, 10.1093/hmg/ddr299 · DOI · Paper page
- Lagier-Tourenne, 2013, Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration, Proc. Natl. Acad. Sci. USA, 110, E4530, 10.1073/pnas.1318835110 · DOI · Paper page
- Freibaum, 2017, The Role of Dipeptide Repeats in C9ORF72-Related ALS-FTD, Front. Mol. Neurosci., 10, 35, 10.3389/fnmol.2017.00035 · DOI · Paper page
- Ash, 2013, Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS, Neuron, 77, 639, 10.1016/j.neuron.2013.02.004 · DOI · Paper page
- Scaber, 2016, What is the role of TDP-43 in C9orf72-related amyotrophic lateral sclerosis and frontemporal dementia?, Brain, 139, 3057, 10.1093/brain/aww264 · DOI
- Gijselinck, 2012, A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study, Lancet Neurol., 11, 54, 10.1016/S1474-4422(11)70261-7 · DOI · Paper page
- Brettschneider, 2012, Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion, Acta Neuropathol., 123, 825, 10.1007/s00401-012-0970-z · DOI · Paper page
- Liu, 2016, C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD, Neuron, 90, 521, 10.1016/j.neuron.2016.04.005 · DOI · Paper page
- Hu, 2017, Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs, Nucleic Acid Ther., 27, 87, 10.1089/nat.2016.0655 · DOI
- Hu, 2015, Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus, Chem. Biol., 22, 1505, 10.1016/j.chembiol.2015.09.016 · DOI
- Graves, 2012, Biogenesis of mammalian microRNAs: a global view, Genomics Proteomics Bioinformatics, 10, 239, 10.1016/j.gpb.2012.06.004 · DOI
- Martier, 2019, Artificial microRNAs targeting C9ORF72 have the potential to reduce accumulation of the intra-nuclear transcripts in ALS and FTD patients, Mol. Ther. Nucleic Acids, 10.1016/j.omtn.2019.01.010 · DOI
- Lee, 2017, Modeling ALS and FTD with iPSC-derived neurons, Brain Res., 1656, 88, 10.1016/j.brainres.2015.10.003 · DOI · Paper page
- Di Giorgio, 2008, Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation, Cell Stem Cell, 3, 637, 10.1016/j.stem.2008.09.017 · DOI · Paper page
- Selvaraj, 2017, Modeling the C9ORF72 repeat expansion mutation using human induced pluripotent stem cells, Brain Pathol., 27, 518, 10.1111/bpa.12520 · DOI
- Peters, 2015, Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice, Neuron, 88, 902, 10.1016/j.neuron.2015.11.018 · DOI · Paper page
- Lee, 2004, MicroRNA genes are transcribed by RNA polymerase II, EMBO J., 23, 4051, 10.1038/sj.emboj.7600385 · DOI · Paper page
- Kim, 2006, Genomics of microRNA, Trends Genet., 22, 165, 10.1016/j.tig.2006.01.003 · DOI · Paper page
- Winter, 2009, Many roads to maturity: microRNA biogenesis pathways and their regulation, Nat. Cell Biol., 11, 228, 10.1038/ncb0309-228 · DOI · Paper page
- Tyzack, 2016, Human Stem Cell-Derived Astrocytes: Specification and Relevance for Neurological Disorders, Curr. Stem Cell Rep., 2, 236, 10.1007/s40778-016-0049-1 · DOI · Paper page
- Xu, 2013, Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration, Proc. Natl. Acad. Sci. USA, 110, 7778, 10.1073/pnas.1219643110 · DOI · Paper page
- van Blitterswijk, 2015, Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72, Acta Neuropathol., 130, 863, 10.1007/s00401-015-1480-6 · DOI · Paper page
- Rizzu, 2016, C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9orf72, MAPT and GRN mutation carriers, Acta Neuropathol. Commun., 4, 37, 10.1186/s40478-016-0306-7 · DOI · Paper page
- Dodge, 2010, AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice, Mol. Ther., 18, 2075, 10.1038/mt.2010.206 · DOI · Paper page
- Koppers, 2015, C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits, Ann. Neurol., 78, 426, 10.1002/ana.24453 · DOI · Paper page
- O’Rourke, 2016, C9orf72 is required for proper macrophage and microglial function in mice, Science, 351, 1324, 10.1126/science.aaf1064 · DOI · Paper page
- Niblock, 2016, Retention of hexanucleotide repeat-containing intron in C9orf72 mRNA: implications for the pathogenesis of ALS/FTD, Acta Neuropathol. Commun., 4, 18, 10.1186/s40478-016-0289-4 · DOI
- Fratta, 2012, C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms RNA G-quadruplexes, Sci. Rep., 2, 1016, 10.1038/srep01016 · DOI · Paper page
- Reddy, 2013, The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures, J. Biol. Chem., 288, 9860, 10.1074/jbc.C113.452532 · DOI · Paper page
- Su, 2014, Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS, Neuron, 83, 1043, 10.1016/j.neuron.2014.07.041 · DOI · Paper page
- Nordin, 2017, Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study, Amyotroph. Lateral Scler. Frontotemporal Degener., 18, 256, 10.1080/21678421.2016.1262423 · DOI
- Prudencio, 2015, Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS, Nat. Neurosci., 18, 1175, 10.1038/nn.4065 · DOI · Paper page
- Han, 2004, The Drosha-DGCR8 complex in primary microRNA processing, Genes Dev., 18, 3016, 10.1101/gad.1262504 · DOI · Paper page
- Liu, 2018, Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer, Mol. Cancer, 17, 64, 10.1186/s12943-018-0765-5 · DOI · Paper page
- Schraivogel, 2014, Import routes and nuclear functions of Argonaute and other small RNA-silencing proteins, Trends Biochem. Sci., 39, 420, 10.1016/j.tibs.2014.07.004 · DOI
- Miniarikova, 2016, Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington’s Disease, Mol. Ther. Nucleic Acids, 5, e297, 10.1038/mtna.2016.7 · DOI · Paper page
- Pascual-Lucas, 2014, Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice, EMBO Mol. Med., 6, 1246, 10.15252/emmm.201404228 · DOI · Paper page
Cited by
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122
Risk factors and emerging therapies in amyotrophic lateral sclerosis
Nowicka, N., Juranek, J., Juranek, J. K., & Wojtkiewicz, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112616 · Cited by 106
“The results of the study indicate that the therapy used may mitigate the RNA-mediated toxicity in the cell nucleus in ALS patients [150].”
Rising Stars: Astrocytes as a Therapeutic Target for ALS Disease
Izrael, M., Slutsky, S. G., & Revel, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00824 · Cited by 73
miR-124: A Promising Therapeutic Target for Central Nervous System Injuries and Diseases
Xu, J., Zheng, Y., Wang, L., Liu, Y., Wang, X., Li, Y., & Chi, G. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01091-6 · Cited by 55
Approaches to gene modulation therapy for ALS
Meijboom, K. E., & Brown, R. H. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01285-w · Cited by 38
“They next treated C9ORF72 mutant BAC transgenic mice with amiRNAs targeting all C9ORF72 transcript variants and demonstrated significant silencing of repeatcontaining C9ORF72 and total C9ORF72 transcripts, and a significant reduction of RNA foci after treatment [142].”
BackgroundMethod
Metadata
- Authors
- Martier, R., Liefhebber, J. M., García-Osta, A., Miniarikova, J., Cuadrado-Tejedor, M., Espelosin, M., Ursua, S., Petry, H., van Deventer, S. J., Evers, M. M., & Konstantinova, P.
- Venue
- Molecular Therapy - Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 16
- Pages
- 26-37
- ISSN
- 2162-2531 (ISSN-L)
- OpenAlex
- W2914096858
- Cited by
- 89
- References
- 19
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. https://app.cochat.ai/papers/10.1016/j.omtn.2019.02.001
- The paper
- Martier, R., Liefhebber, J. M., García-Osta, A., Miniarikova, J., Cuadrado-Tejedor, M., Espelosin, M., Ursua, S., Petry, H., van Deventer, S. J., Evers, M. M., & Konstantinova, P. (2019). Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Molecular Therapy - Nucleic Acids. https://doi.org/10.1016/j.omtn.2019.02.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.